Lung Cancer

Patients with advanced non–small-cell lung cancer (NSCLC) achieved a significant increase in overall survival when tumor treating fields (TTF) therapy was added to pemetrexed every 3 weeks, according to data released by Novocure at the European Society for Medical Oncology Congress.
 
Page 12 of 12
Results 111 - 111 of 111